<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635892</url>
  </required_header>
  <id_info>
    <org_study_id>18-254</org_study_id>
    <nct_id>NCT03635892</nct_id>
  </id_info>
  <brief_title>A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma</brief_title>
  <official_title>A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare any good and bad effects of using a combination of&#xD;
      nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single institution open-label phase II trial of cabozantinib and nivolumab in patients with advanced or metastatic non-clear cell Renal Cell Carcinoma (nccRCC), who have not received prior PD-1/PD-L1 directed therapy. This study is designed as separate cohorts defined by histology across three cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years</time_frame>
    <description>per RECIST v1.1</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma</condition>
  <condition>Unclassified Renal Cell Carcinoma</condition>
  <condition>Papillary Renal Cell Carcinoma</condition>
  <condition>Fumarate Hydratase Deficient Renal Cell Carcinoma</condition>
  <condition>Succinate Dehydrogenase Deficient Renal Cell Carcinoma</condition>
  <condition>Collecting Duct Renal Cell Carcinoma</condition>
  <condition>Chromophobe Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Unclassified, papillary, and HL RCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Chromophobe RCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Unclassified, papillary, and HL RCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Unclassified, papillary, and HL RCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabozantinib</intervention_name>
    <description>cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.</description>
    <arm_group_label>Cohort 1: Unclassified, papillary, and HL RCC</arm_group_label>
    <arm_group_label>Cohort 2: Chromophobe RCC</arm_group_label>
    <arm_group_label>Cohort 3: Unclassified, papillary, and HL RCC</arm_group_label>
    <arm_group_label>Cohort 4: Unclassified, papillary, and HL RCC</arm_group_label>
    <other_name>CABOMETYX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.</description>
    <arm_group_label>Cohort 1: Unclassified, papillary, and HL RCC</arm_group_label>
    <arm_group_label>Cohort 2: Chromophobe RCC</arm_group_label>
    <arm_group_label>Cohort 3: Unclassified, papillary, and HL RCC</arm_group_label>
    <arm_group_label>Cohort 4: Unclassified, papillary, and HL RCC</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated IRB-approved Informed Consent Form&#xD;
&#xD;
          -  Pathologic or histologically confirmed unresectable advanced or metastatic nccRCC&#xD;
&#xD;
          -  0 or 1 prior systemic therapies, including treatment in the adjuvant setting&#xD;
&#xD;
          -  Availability of a representative formalin fixed, paraffin embedded tumor specimen or&#xD;
             fresh frozen tissue specimen that enables the definitive diagnosis of RCC, accompanied&#xD;
             by an associated pathology report. Specimens can be collected by surgical resection or&#xD;
             biopsy of the primary tumor or biopsy or resection of a metastatic lesion.&#xD;
&#xD;
          -  Measurable disease, as defined by RECIST 1.1&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  KPS ≥ 70&#xD;
&#xD;
          -  Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior&#xD;
             treatments, unless adverse events (AE(s)) are clinically nonsignificant and/or stable&#xD;
             on supportive therapy.&#xD;
&#xD;
          -  Adequate hematologic and end organ function, defined by the following laboratory&#xD;
             results obtained within 14 days prior to the first study treatment:&#xD;
&#xD;
               -  ANC ≥ 1500 cells/μL (without granulocyte colony stimulating factor support within&#xD;
                  2 weeks prior to Cycle 1, Day 1)&#xD;
&#xD;
               -  WBC counts ≥ 2500/μL and ≤ 15,000/μL without G-CSF&#xD;
&#xD;
               -  Lymphocyte count ≥ 500/μL&#xD;
&#xD;
               -  Platelet count ≥100,000/μL (without transfusion within 2 weeks prior to Cycle 1,&#xD;
                  Day 1)&#xD;
&#xD;
               -  Hemoglobin ≥9.0 g/dL (without transfusion within 2 weeks prior to Cycle 1, Day 1)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline&#xD;
             phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN if patient has&#xD;
             documented bone metastases.&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 x ULN . Patients with known Gilbert disease who have serum&#xD;
             bilirubin level ≤ 3 x ULN may be enrolled.&#xD;
&#xD;
          -  Serum albumin ≥ 2.8 g/dl&#xD;
&#xD;
          -  Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be&#xD;
             enrolled.&#xD;
&#xD;
          -  INR and aPTT ≤ 1.3 x ULN • within 14 days of first dose of study treatment.This&#xD;
             applies only to patients who are not receiving therapeutic anticoagulation; patients&#xD;
             receiving therapeutic anticoagulation should be on a stable dose.&#xD;
&#xD;
          -  Creatinine ≤ 2.0 x ULN or Calculated Creatinine clearance ≥ 30mL/min&#xD;
&#xD;
          -  For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile&#xD;
             (absence of ovaries and/or uterus): agreement to use two adequate methods of&#xD;
             contraception, including at least one method with a failure rate of ≥ 1% per year&#xD;
&#xD;
          -  Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)&#xD;
&#xD;
          -  Sexually active fertile subjects and their partners must agree to use medically&#xD;
             accepted methods of contraception (eg, barrier methods, including male condom, female&#xD;
             condom, or diaphragm with spermicidal gel) during the course of the study and for 5&#xD;
             months after the last dose of study treatment for females and 7 months for males.&#xD;
&#xD;
          -  Female subjects of childbearing potential must not be pregnant at screening. Females&#xD;
             of childbearing potential are defined as premenopausal females capable of becoming&#xD;
             pregnant (ie, females who have had any evidence of menses in the past 12 months, with&#xD;
             the exception of those who are surgically sterile as described above).&#xD;
&#xD;
        However, women who have been amenorrheic for 12 or more months are still considered to be&#xD;
        of childbearing potential if the amenorrhea is possibly due to prior chemotherapy,&#xD;
        antiestrogens, low body weight, ovarian suppression or other reasons.&#xD;
&#xD;
          -  Capable of understanding and complying with the protocol requirements and must have&#xD;
             signed the informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with an immunotherapy agent including high dose IL-2, anti-CTLA-4,&#xD;
             anti-PD1, and anti-PD-L1 agents&#xD;
&#xD;
          -  Prior treatment with cabozantinib for non-clear cell RCC&#xD;
&#xD;
          -  Receipt of any type of small molecule kinase inhibitor within 2 weeks of treatment.&#xD;
&#xD;
          -  Receipt of any type of anti-cancer antibody, cytotoxic anticancer therapy, or any&#xD;
             other investigational agents within 4 weeks of treatment start&#xD;
&#xD;
          -  Known malignancies of the brain or spinal cord or leptomeningeal disease&#xD;
&#xD;
          -  Patients requiring pain medication must be on a stable regimen at study entry&#xD;
&#xD;
          -  Systemic treatment with corticosteroids (&gt; 10 mg daily prednisone equivalents) or&#xD;
             other immunosuppressive medications within 14 days prior to first dose of study drug.&#xD;
             Inhaled steroids and adrenal replacement steroids &gt; 10 mg daily prednisone equivalents&#xD;
             are allowed in the absence of autoimmune disease&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently)&#xD;
&#xD;
          -  Uncontrolled hypercalcemia (≥ 1.5 mmol/L ionized calcium or Ca ≥ 12 mg/dL or corrected&#xD;
             serum calcium ≥ ULN) or symptomatic hypercalcemia requiring continued use of&#xD;
             bisphosphonate therapy or denosumab&#xD;
&#xD;
          -  Diagnosis of another malignancy within 2 years before first dose of study treatment,&#xD;
             except for superficial skin cancers, or localized, low grade tumors deemed cured and&#xD;
             not treated with systemic therapy&#xD;
&#xD;
          -  Pregnant and lactating women History of severe allergic, anaphylactic, or other&#xD;
             hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Patients with active or chronic hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease&#xD;
             (Class II or greater), myocardial infarction within the previous 6 months, unstable&#xD;
             arrhythmias, unstable angina, or EF &lt; 50%&#xD;
&#xD;
          -  Uncontrolled hypertension defined as sustained blood pressure (BP) &gt; 150 mm Hg&#xD;
             systolic or &gt; 100 mm Hg diastolic despite optimal antihypertensive treatment&#xD;
&#xD;
          -  Patients with known coronary artery disease, congestive heart failure not meeting the&#xD;
             above criteria must be on a stable medical regimen that is optimized in the opinion of&#xD;
             the treating physician, in consultation with a cardiologist if appropriate&#xD;
&#xD;
          -  Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks&#xD;
             before first dose of study treatment. Complete wound healing from major surgery must&#xD;
             have occurred 1 month before first dose and from minor surgery (eg, simple excision,&#xD;
             biopsy, tooth extraction) at least 10 days before first dose. Subjects with clinically&#xD;
             relevant ongoing complications from prior surgery are not eligible&#xD;
&#xD;
          -  History of stroke or transient ischemic attack within 6 months prior to Cycle 1, Day 1&#xD;
&#xD;
          -  Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or&#xD;
             recent peripheral arterial thrombosis) within 6 months prior to Cycle 1, Day 1&#xD;
&#xD;
          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             therapeutic anticoagulation)&#xD;
&#xD;
          -  Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine&#xD;
             parenteral hydration, parenteral nutrition, or tube feeding&#xD;
&#xD;
          -  Evidence of abdominal free air not explained by paracentesis or recent surgical&#xD;
             procedure&#xD;
&#xD;
          -  Patients with a history of abdominal fistula, gastrointestinal perforation, or&#xD;
             intraabdominal abscess within 6 months prior to study enrollment&#xD;
&#xD;
          -  Other clinically significant disorders that would preclude safe study participation&#xD;
&#xD;
               -  Serious non-healing wound/ulcer/bone fracture&#xD;
&#xD;
               -  Uncompensated/symptomatic hypothyroidism&#xD;
&#xD;
               -  Moderate to severe hepatic impairment (Child-Pugh B or C)&#xD;
&#xD;
          -  Corrected QT interval calculated by the Frederica formula (QTcF) &gt; 500 ms per&#xD;
             elFectrocardiogram (ECG) within 28 days before first dose of study treatment Note: If&#xD;
             a single ECG shows a QTcF with an absolute value &gt; 500 ms, two additional ECGs at&#xD;
             intervals of approximately 3 min must be performed within 30 min after the initial&#xD;
             ECG, and the average of these three consecutive results for QTcF will be used to&#xD;
             determine eligibility&#xD;
&#xD;
          -  Inability to swallow tablets or capsules&#xD;
&#xD;
          -  Previously identified allergy or hypersensitivity to components of the study treatment&#xD;
             formulations&#xD;
&#xD;
          -  Patients with a history of non-compliance to medical regimens or who are considered&#xD;
             potentially unreliable or will not be able to complete the entire study&#xD;
&#xD;
          -  Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin&#xD;
             inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet&#xD;
             inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:&#xD;
&#xD;
               -  Low-dose aspirin for cardio protection (per local applicable guidelines) is&#xD;
                  permitted&#xD;
&#xD;
               -  Low-dose low molecular weight heparins (LMWH) are permitted&#xD;
&#xD;
               -  Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors&#xD;
                  rivaroxaban, edoxaban, or apixaban allowed in subjects without known brain&#xD;
                  metastases who are on a stable dose of LMWH for at least 1 week before first dose&#xD;
                  of study treatment, and who have had no clinically significant hemorrhagic&#xD;
                  complications from the anticoagulation regimen or the tumor&#xD;
&#xD;
          -  Clinically significant hematuria, hematemesis, or hemoptysis of &gt; 0.5 teaspoon (2.5&#xD;
             ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage)&#xD;
             within 12 weeks before first dose&#xD;
&#xD;
          -  Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease&#xD;
             manifestation&#xD;
&#xD;
          -  The subject has tumor invading or encasing any major blood vessels&#xD;
&#xD;
          -  The subject has evidence of tumor invading the GI tract (esophagus, stomach, small or&#xD;
             large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor&#xD;
             within 28 days before the first dose of cabozantinib&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;150 mmHg systolic or &gt; 100 mmHg diastolic despite optimal&#xD;
             antihypertensive treatment)&#xD;
&#xD;
          -  Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy&#xD;
             within 4 weeks before first dose of study treatment. Systemic treatment with&#xD;
             radionuclides within 6 weeks before the first dose of study treatment. Subjects with&#xD;
             clinically relevant ongoing complications from prior radiation therapy are not&#xD;
             eligible. Radiation for palliation is allowable on study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung-Han Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chung-Han Lee, MD, PhD</last_name>
    <phone>646-497-9068</phone>
    <email>leec4@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Motzer, MD</last_name>
    <phone>646-888-4722</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Han Lee, MD, PhD</last_name>
      <phone>646-497-9068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Han Lee, MD, PhD</last_name>
      <phone>646-497-9068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Han Lee, MD, PhD</last_name>
      <phone>646-497-9068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Han Lee, MD,PhD</last_name>
      <phone>646-497-9068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Han Lee, MD, PhD</last_name>
      <phone>646-497-9068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Han Lee, MD, PhD</last_name>
      <phone>646-497-9068</phone>
    </contact>
    <contact_backup>
      <last_name>Robert Motzer, MD</last_name>
      <phone>646-888-4722</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Han Lee, MD, PhD</last_name>
      <phone>646-497-9068</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Cabozantinib</keyword>
  <keyword>18-254</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

